Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update

What happened: Marvel Biosciences signed a letter of intent with Novatech, an Asia-Pacific clinical CRO, to run a Phase 1 trial of MB-204 in Australia. The company also gave a corporate update. Key numbers: Phase 1 single ascending dose study expected to begin in Q4 of 2026. Australia offers a 43% tax credit. Why it matters: The LOI moves MB-204 from preclinical work toward first-in-human testing, which Marvel's CEO called the company's transition from a preclinical to a clinical phase company.

Marvel Biosciences signed a letter of intent with Novatech, an Asia-Pacific clinical CRO, to run a Phase 1 trial of MB-204 in Australia. The company also gave a corporate update.

The LOI moves MB-204 from preclinical work toward first-in-human testing, which Marvel's CEO called the company's transition from a preclinical to a clinical phase company.